604 related articles for article (PubMed ID: 16315241)
1. The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases.
Wiering B; Krabbe PF; Jager GJ; Oyen WJ; Ruers TJ
Cancer; 2005 Dec; 104(12):2658-70. PubMed ID: 16315241
[TBL] [Abstract][Full Text] [Related]
2. Controversies in the management of colorectal liver metastases: role of PET and PET/CT.
Wiering B; Vogel WV; Ruers TJ; Oyen WJ
Dig Surg; 2008; 25(6):413-20. PubMed ID: 19212113
[TBL] [Abstract][Full Text] [Related]
3. Value of positron emission tomography with [F-18]fluorodeoxyglucose in patients with colorectal liver metastases: a prospective study.
Ruers TJ; Langenhoff BS; Neeleman N; Jager GJ; Strijk S; Wobbes T; Corstens FH; Oyen WJ
J Clin Oncol; 2002 Jan; 20(2):388-95. PubMed ID: 11786565
[TBL] [Abstract][Full Text] [Related]
4. Role of FDG-PET in the diagnosis and treatment of colorectal liver metastases.
Wiering B; Ruers TJ; Oyen WJ
Expert Rev Anticancer Ther; 2004 Aug; 4(4):607-13. PubMed ID: 15270664
[TBL] [Abstract][Full Text] [Related]
5. Assessment of local control after laser-induced thermotherapy of liver metastases from colorectal cancer: contribution of FDG-PET in patients with clinical suspicion of progressive disease.
Denecke T; Steffen I; Hildebrandt B; Rühl R; Streitparth F; Lehmkuhl L; Langrehr J; Ricke J; Amthauer H; Hänninen EL
Acta Radiol; 2007 Oct; 48(8):821-30. PubMed ID: 17924212
[TBL] [Abstract][Full Text] [Related]
6. Survival of patients evaluated by FDG-PET before hepatic resection for metastatic colorectal carcinoma: a prospective database study.
Strasberg SM; Dehdashti F; Siegel BA; Drebin JA; Linehan D
Ann Surg; 2001 Mar; 233(3):293-9. PubMed ID: 11224615
[TBL] [Abstract][Full Text] [Related]
7. The role of FDG-PET in the selection of patients with colorectal liver metastases.
Wiering B; Krabbe PF; Dekker HM; Oyen WJ; Ruers TJ
Ann Surg Oncol; 2007 Feb; 14(2):771-9. PubMed ID: 17086488
[TBL] [Abstract][Full Text] [Related]
8. Preoperative staging of patients with liver metastases of colorectal carcinoma. Does PET/CT really add something to multidetector CT?
Ramos E; Valls C; Martinez L; Lladó L; Torras J; Ruiz S; Gamez C; Serrano T; Fabregat J; Rafecas A
Ann Surg Oncol; 2011 Sep; 18(9):2654-61. PubMed ID: 21431987
[TBL] [Abstract][Full Text] [Related]
9. Utility of 18F-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases.
Fong Y; Saldinger PF; Akhurst T; Macapinlac H; Yeung H; Finn RD; Cohen A; Kemeny N; Blumgart LH; Larson SM
Am J Surg; 1999 Oct; 178(4):282-7. PubMed ID: 10587184
[TBL] [Abstract][Full Text] [Related]
10. Impact of Fluorodeoxyglucose PET/Computed Tomography on the Management of Patients with Colorectal Cancer.
Laurens ST; Oyen WJ
PET Clin; 2015 Jul; 10(3):345-60. PubMed ID: 26099671
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of fluorine-18-deoxyglucose positron emission tomography in detecting tumor recurrence after local ablative therapy for liver metastases: a prospective study.
Langenhoff BS; Oyen WJ; Jager GJ; Strijk SP; Wobbes T; Corstens FH; Ruers TJ
J Clin Oncol; 2002 Nov; 20(22):4453-8. PubMed ID: 12431968
[TBL] [Abstract][Full Text] [Related]
12. Unique site- and time-specific patterns of recurrence following resection of colorectal carcinoma hepatic metastases in patients staged by FDG-PET.
Finkelstein SE; Fernandez FG; Dehdashti F; Siegel BA; Hawkins WG; Linehan DC; Strasberg SM
J Hepatobiliary Pancreat Surg; 2008; 15(5):483-7. PubMed ID: 18836801
[TBL] [Abstract][Full Text] [Related]
13. FDG-PET for detecting local tumor recurrence of ablated liver metastases: a diagnostic meta-analysis.
Poulou LS; Ziakas PD; Ziogas DC; Doxani C; Xyla V; Vakrinos G; Voulgarelis M; Thanos L
Biomarkers; 2012 Sep; 17(6):532-8. PubMed ID: 22712479
[TBL] [Abstract][Full Text] [Related]
14. Improved selection of patients for hepatic surgery of colorectal liver metastases with (18)F-FDG PET: a randomized study.
Ruers TJ; Wiering B; van der Sijp JR; Roumen RM; de Jong KP; Comans EF; Pruim J; Dekker HM; Krabbe PF; Oyen WJ
J Nucl Med; 2009 Jul; 50(7):1036-41. PubMed ID: 19525451
[TBL] [Abstract][Full Text] [Related]
15. The value of FDG positron emission tomography/computerised tomography (PET/CT) in pre-operative staging of colorectal cancer: a systematic review and economic evaluation.
Brush J; Boyd K; Chappell F; Crawford F; Dozier M; Fenwick E; Glanville J; McIntosh H; Renehan A; Weller D; Dunlop M
Health Technol Assess; 2011 Sep; 15(35):1-192, iii-iv. PubMed ID: 21958472
[TBL] [Abstract][Full Text] [Related]
16. Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver?
Selzner M; Hany TF; Wildbrett P; McCormack L; Kadry Z; Clavien PA
Ann Surg; 2004 Dec; 240(6):1027-34; discussion 1035-6. PubMed ID: 15570208
[TBL] [Abstract][Full Text] [Related]
17. The economic impact of 18FDG positron emission tomography in the surgical management of colorectal cancer with hepatic metastases.
Zubeldia JM; Bednarczyk EM; Baker JG; Nabi HA
Cancer Biother Radiopharm; 2005 Aug; 20(4):450-6. PubMed ID: 16114993
[TBL] [Abstract][Full Text] [Related]
18. FDG-PET improves the staging and selection of patients with recurrent colorectal cancer.
Lonneux M; Reffad AM; Detry R; Kartheuser A; Gigot JF; Pauwels S
Eur J Nucl Med Mol Imaging; 2002 Jul; 29(7):915-21. PubMed ID: 12111132
[TBL] [Abstract][Full Text] [Related]
19. The role of [18F]fluorodeoxyglucose positron emission tomography imaging in the evaluation of hepatocellular carcinoma.
Wudel LJ; Delbeke D; Morris D; Rice M; Washington MK; Shyr Y; Pinson CW; Chapman WC
Am Surg; 2003 Feb; 69(2):117-24; discussion 124-6. PubMed ID: 12641351
[TBL] [Abstract][Full Text] [Related]
20. The role of whole-body positron emission tomography with [18F]fluorodeoxyglucose in identifying operable colorectal cancer metastases to the liver.
Lai DT; Fulham M; Stephen MS; Chu KM; Solomon M; Thompson JF; Sheldon DM; Storey DW
Arch Surg; 1996 Jul; 131(7):703-7. PubMed ID: 8678767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
